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We report a case of burning vulvar pain accompanied by erythema responding to an oral combination of a benzodiazepine and a
beta blocker. The positive response to two medication classes used in the treatment of erythromelalgia supports the possibility of
a localized manifestation of this disorder in the genital region.
1.Introduction
Erythromelalgia (EM) is a rare disorder characterized by
episodic erythema of the skin associated with increase in
temperature and burning pain. While EM is thought to
primarily aﬀect the extremities, particularly the hands and
the feet, it has been described in other parts of the body such
as the head, neck, and scrotum.
2. Case Presentation
A 67-year-old Caucasian female presented for evaluation of
persistent burning pain and itching in the vulvar region
accompanied by marked erythema and warmth to the touch
(Figure 1). Her symptoms ﬁrst appeared in childhood but
increased in frequency and severity after menopause. During
her reproductive years, she had experienced a myriad of
urologic and gynecological symptoms. In her 20s, the pre-
ponderance of her symptoms involved her bladder, and she
was subsequently diagnosed with interstitial cystitis. In her
30s,hergynecologicsymptomsbecamemoreprominentand
she was ultimately diagnosed with endometriosis for which
she underwent a hysterectomy and bilateral oophorectomy
at age 33. Throughout this time, her unexplained episodic
vulvar symptoms were present; however, it was not until
menopause that her vulvar symptoms became persistent
and the frequency and severity of her ﬂares dramatically
increased. She found that the application of cold water and
minimizing humidity and warmth in the perineal region
were the only ameliorative modalities consistently eﬀective
in decreasing the frequency and severity of her “ﬂares.” It is
interesting to note that her mother and a maternal aunt had
similarlifelongsymptomswhichtheyhadattributedtohorse
back riding.
On initial evaluation, the patient had normal appearing
vulvar skin and vulvar mucosal changes consistent with
the diagnosis of menopausal atrophy. On examination, she
experienced diﬀuse burning and pain when the vulvar skin
was gently stroked with a cotton swab. For the purpose of
the symptomatic management of worsening burning and
dyspareunia,weprescribedatrialoftopicalestrogen(0.05%)
and lidocaine (5%) compounded in hydrophilic petrolatum.
While this regimen provided some relief, she continued
to experience “ﬂares.” Consequently, the patient was asked2 Case Reports in Medicine
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Figure 1: After treatment with beta-blocker (a). Acute ﬂare (b).
to return upon recurrence of a “ﬂare” for evaluation and
photographic documentation (Figure 1(a)). In the absence
of a known diagnosis, we empirically prescribed bedtime
clonazepam (0.5mg) which improved her overall sense of
well being and decreased the intensity of the ﬂares.
While her symptoms were manageable on clonazepam
for 3 months, a marked improvement occurred only after
a serendipitous change in her antihypertensive regimen.
Within 2 weeks of her primary care provider adding a beta
blocker (nebivolol) to her medical regimen, she noted a
drastic improvement in her symptoms of vulvar burning and
accompanying erythema (Figure 1(b)). To date, more than
six months after the start of beta-blocker, the redness of
her vulvar region has subsided, and her quality of life has
dramatically improved.
3. Discussion
Given the uncommon occurrence and possible failure to rec-
ognize mild symptoms, accurate estimates of the incidence
andprevalenceofEMarediﬃculttoobtain.Itisthoughtthat
the condition occurs most commonly in women, and while
it can present at any age, it is most often seen in the ﬁfth and
sixth decades of life [1]. Though primarily thought to aﬀect
the extremities, EM has also been described in the ears, face,
and most recently the scrotum [1, 2].
T h ee t i o l o g yo fE Mi sn o tw e l lu n d e r s t o o da n dc o n -
sequently EM is often a diagnosis of exclusion. EM is
clinically classiﬁed into primary and secondary subtypes [3].
Primary EM is thought to be due to a genetic susceptibility
on chromosome 2 that results in a mutation of the gene
that codes for voltage gated sodium channels [4–6]. This
mutation leads to a dysfunction of vasomotor regulation
and results in a shunting process. Symptoms of primary EM
usually present early in life are symmetric and alleviated by
cold. Secondary EM is thought to arise from medication use,
hematologic or connective tissue disorders, or neuropathies
[7]. For example, EM associated with thrombocythemia has
been described in polycythemia vera [8]. In this setting,
symptoms are more likely to be unilateral and initially
present as itching and prickling that evolves into severe
burning pain and warmth to the touch. Our patient’s
symptomsappeartobeamixofbothprimaryandsecondary
EM: she has a lifelong history of symmetric symptoms
alleviated by cold and an itching as well as prickling pain that
has evolved into severe burning pain during her ﬁfth decade
of life. It is important to note that while recognized as an
importantmarkerofsecondaryEM,hemoglobinandplatelet
counts were not checked in this patient. Her blood work has
been monitored by her primary care provider as a part of
the general management of her hypertension. To date, there
hasbeennoreportofclottingdisordersorotherhematologic
conditions that might further complicate the clinical picture
of this patient. Additionally, given that this patient presented
for the treatment of lifelong vulvar pain, other medications,
often used in the treatment of EM such as calcium channel
blockers and highdose aspirin were not utilized.
4. Conclusion
While there has been recent progress in understanding
EM, patients and healthcare providers continue to ﬁnd the
treatment and management quite frustrating. There is no
single medication, combination of medications or method
of treatment that has been found to be universally helpful in
patients suﬀering from EM [1, 9]. Therefore, providers often
rely upon trial and error.
While a universally eﬀective treatment regimen for EM
has not been established, beta blockers and centrally acting
agents (such as anticonvulsants and benzodiazepine) are
among the numerous medications that have illustrated
clinical eﬃcacy in the management of the signs and
symptoms of EM [9–12]. Our patient has had remarkable
improvement of her lifelong symptoms on a combinationCase Reports in Medicine 3
of a beta blocker and a benzodiazepine. This improvement
has persisted for greater than six months (to date). It is
noted that nebivolol, in contrast with other beta blockers,
is known to have vasodilatory eﬀects. We cannot postulate
a speciﬁc mechanism that would account for the dramatic
response but hypothesize that diﬀerential responses to beta
blockersensitivitythathavebeenobservedacrossindividuals
may play a role. Our patient’s presentation and treatment
response suggests that EM may similarly occur in the vulvar
region as it does in the scrotum. However, the clinical
course and genital manifestation of EM may diﬀer from its
presentation in extremity leading to additional diagnostic
challenges in genitalia.
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